Estradiol stimulates apolipoprotein A-I- but not A-II-containing particle synthesis and secretion by stimulating mRNA transcription rate in Hep G2 cells

Arteriosclerosis, Thrombosis, and Vascular Biology
F Y JinM L Kashyap

Abstract

Estrogen therapy increases plasma HDL levels, which may reduce cardiovascular risk in postmenopausal women. The mechanism of action of estrogen in influencing various steps in hepatic HDL and apolipoprotein (apo) A-I synthesis and secretion are not fully understood. In this study, we have used the human hepatoblastoma cell line (Hep G2) as an in vitro model system to delineate the effect of estradiol on multiple regulatory steps involved in hepatic HDL metabolism. Incubation of Hep G2 cells with estradiol resulted in the following statistically significant findings: (1) increased accumulation of apoA-I in the medium without affecting uptake/removal of radiolabeled HDL-protein; (2) accelerated incorporation of [3H]leucine into apoA-I; (3) selective increase in [3H]leucine incorporation into lipoprotein (LP) A-I but not LP A-I+A-II HDL particles (HDL particles without and with apoA-II, respectively); (4) increased ability of apoA-I-containing particles to efflux cholesterol from fibroblasts; (5) stimulated steady state apoA-I but not apoA-II mRNA expression; and (6) increased newly transcribed apoA-I mRNA message without effect on apoA-I mRNA half-life. The data indicate that estradiol stimulates newly transcribed hepatic apoA-I ...Continue Reading

References

Dec 15, 1992·Annals of Internal Medicine·D GradyS R Cummings
Nov 1, 1991·The Journal of Clinical Endocrinology and Metabolism·R A Lobo
Nov 9, 1989·The New England Journal of Medicine·D J Gordon, B M Rifkind
Jan 15, 1987·Biochemical and Biophysical Research Communications·R BarbarasG Ailhaud
May 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·S P TamR G Deeley
Nov 1, 1987·Atherosclerosis·P PuchoisJ C Fruchart
May 1, 1985·The Journal of Clinical Investigation·K SakuM L Kashyap
Aug 1, 1983·The Journal of Clinical Endocrinology and Metabolism·E J SchaeferR I Levy
Jun 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·C J Fielding, P E Fielding
Jun 1, 1982·The Journal of Clinical Endocrinology and Metabolism·M J TikkanenS U Sipinen
Jun 1, 1995·Current Opinion in Lipidology·F M SacksB W Walsh
Jun 1, 1994·Current Opinion in Lipidology·F M Sacks, B W Walsh

❮ Previous
Next ❯

Citations

Mar 29, 2002·The New England Journal of Medicine·Ronald M Krauss
Dec 13, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Stefania Lamon-FavaErnst J Schaefer
Oct 18, 2003·Journal of Lipid Research·Stefania Lamon-Fava, Dale Micherone
Mar 20, 2004·Expert Review of Cardiovascular Therapy·Shaista Malik, Moti L Kashyap
Mar 27, 2001·Current Opinion in Lipidology·V I ZannisD Kardassis
Apr 19, 2016·Clinical Endocrinology·Panagiotis AnagnostisIan F Godsland
Jan 23, 1999·The American Journal of Cardiology·M L Kashyap
Apr 8, 2003·The American Journal of Cardiology·Daniel J Rader
Jun 17, 2008·Metabolism: Clinical and Experimental·Shucun QinMoti L Kashyap

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.